Coherus BioSciences (FRA:8C5) EV-to-Revenue : 1.16 (As of Jan. 19, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Coherus BioSciences's enterprise value is €322.6 Mil. Coherus BioSciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €279.0 Mil. Therefore, Coherus BioSciences's EV-to-Revenue for today is 1.16.

The historical rank and industry rank for Coherus BioSciences's EV-to-Revenue or its related term are showing as below:

FRA:8C5' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.74 Med: 4.28 Max: 872.38
Current: 1.09

During the past 12 years, the highest EV-to-Revenue of Coherus BioSciences was 872.38. The lowest was 0.74. And the median was 4.28.

FRA:8C5's EV-to-Revenue is ranked better than
84.34% of 1041 companies
in the Biotechnology industry
Industry Median: 7.11 vs FRA:8C5: 1.09

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-01-19), Coherus BioSciences's stock price is €1.3605. Coherus BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €2.40. Therefore, Coherus BioSciences's PS Ratio for today is 0.57.

Coherus BioSciences EV-to-Revenue Historical Data

The historical data trend for Coherus BioSciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences EV-to-Revenue Chart

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.59

2.39

3.77

4.33

2.86

Coherus BioSciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-Revenue	Get a 7-Day Free Trial															3.58	2.86	1.63	1.01	0.96

Competitive Comparison of Coherus BioSciences's EV-to-Revenue

For the Biotechnology subindustry, Coherus BioSciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's EV-to-Revenue falls into.

Coherus BioSciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Coherus BioSciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	322.615	/	278.958
	=	1.16

Coherus BioSciences's current Enterprise Value is €322.6 Mil.
Coherus BioSciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €279.0 Mil.

Coherus BioSciences (FRA:8C5) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Coherus BioSciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.3605	/	2.395
	=	0.57

Coherus BioSciences's share price for today is €1.3605.
Coherus BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.40.

Coherus BioSciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Coherus BioSciences Headlines

No Headlines